What My Patients Are Asking: What Is the Lung Inflammation Side Effect Caused by CDK4/6 Inhibitors?
In September 2019, the U.S. Food and Drug Administration released a statement warning that the CDK4/6 inhibitors used to treat breast cancer:
Ibrance (chemical name: palbociclib)
Kisqali (chemical name: ribociclib)
Verzenio (chemical name: abemaciclib)
may cause rare but serious inflammation in the lungs.
Listen to the podcast to hear Dr. Wojciechowski talk about:
how CDK4/6 inhibitors are used to treat breast cancer
why we’re just hearing about this side effect now
he recommendations for anyone being treated with a CDK4/6 inhibitor
Dr. Wojo is a medical oncologist outside of Philadelphia, PA, with Crozer Health. His research has been presented at the San Antonio Breast Cancer Symposium, and he is a speaker on medical ethics and the biology of cancer. Dr. Wojo sees cancer as a scientifically complex disease with psychological, social, and spiritual dimensions.
— Last updated on January 12, 2022, 7:34 PM